In English | En español
Questions About Cancer? 1-800-4-CANCER

Clinical Trials (PDQ®)

Page Options

  • Print This Page
  • Email This Document
Clinical Trial Questions?
Get Help:
LiveHelp online chat
A Clinical Study of PHY906 as a Modulator of CPT-11 in Patients With Metastatic Colorectal Cancer

Basic Trial Information
Trial Description
     Eligibility Criteria
Trial Contact Information

Basic Trial Information

PhaseTypeStatusAgeSponsorProtocol IDs
Phase II, Phase ITreatmentActive18 and overOther0706002781
ACS IRG 58-012-49, NCT00730158

Trial Description


PHY906 is an oral form of a spray dried aqueous extract composed of four main herbs, which have been used in the Orient for nearly 2000 years for a variety of GI symptoms including diarrhea and nausea/vomiting. Extensive pre-clinical research has been done with Chinese herbal medicine, and studies have documented significant anticancer activity in combination with various cytotoxic agents including CPT-11, which is a semi-synthetic derivative of the natural alkaloid camptothecin and belongs to the class of topoisomerase I inhibitors. The proposed plan will investigate the mechanism and efficacy of Chinese herbal medicine as an adjunct to chemotherapy in treatment of patients with metastatic colorectal cancer. Our rationale for the therapeutic use of PHY906 is its potential activity in reducing chemotherapy-induced toxicity, especially diarrhea.

Eligibility Criteria

Inclusion Criteria:

  • Patients must have histologically confirmed malignancy that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective (Phase I Part).
  • Patients with histologically confirmed metastatic colorectal cancer, who failed with prior two different chemotherapy regimens (Phase II Part).
  • At least one evaluable lesion. Lesions must be evaluated by computerized tomography (CT), magnetic resonance imaging (MRI), or PET scan (Phase I Part).
  • At least one measurable lesion by CT or MRI of ≥ 20 mm (if conventional CT scan) or ≥ 10 mm (if spiral CT scan) (Phase II part)
  • Karnofsky Performance Status ≥ 60%
  • Must be ≥18 years of age.
  • Expected survival of at least 3 months for phase I part, and at least 6 months for phase II part.
  • Women of child-bearing potential (i.e., women who are pre-menopausal or not surgically sterile) must use acceptable contraceptive methods (abstinence, intrauterine device [IUD], oral contraceptive or double barrier device), and must have a negative serum or urine pregnancy test within 1 week prior to beginning treatment on this trial. Nursing patients are excluded. Sexually active men must also use acceptable contraceptive methods. Pregnant and nursing patients are excluded because the effects of the combination of PHY906 and CPT-11 on a fetus or nursing child are unknown.
  • Must be able and willing to give written informed consent.
  • Patients must have the following clinical laboratory values:

ANC count ≥ 1,500/ mm3. Platelets ≥ 100,000/ mm3. Serum creatinine ≤ 2x upper limit of normal. Total bilirubin < 1.5x upper limit of normal. Serum calcium < 12.0 mg/dl. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3x the upper limit of normal (≤ 5.0 x ULN is acceptable if liver has tumor involvement) Prothrombin Time (PT), activated partial thromboplastin time (aPTT) and INR ≤ 1.5 x ULN or in the therapeutic range if on anticoagulation Hemoglobin ≥ 9 gm/dl (may be corrected by transfusion).

Exclusion Criteria:

  • Symptomatic brain metastasis.
  • Serious concomitant systemic disorders (e.g., active infection) that, in the opinion of the investigator, would compromise the safety of the patient or compromise the patient's ability to complete the study.
  • Unwilling or unable to follow protocol requirements or to give informed consent.
  • No treatment with cytotoxic or biologic agents within the 4 weeks prior to beginning treatment on this study (6 weeks for mitomycin or nitrosoureas). At least 4 weeks must have elapsed from any prior surgery, radiation, hormonal or other drug therapy for their cancer.
  • Known HIV positivity, as safety in this patient population has not been assessed.
  • Presence of metastatic disease that, in the opinion of investigators, would require palliative treatment within 4 weeks of enrollment.
  • Altered mental status precluding understanding of the informed consent process and/or completion of the necessary studies.
  • Pregnant or breast-feeding women.
  • Men and women of childbearing age and potential, who are not willing to use effective contraception.
  • Major surgery within the last 4 weeks.
  • Patients taking concurrent medications of any kind which are strong inducers or inhibitors of CYP3A4. Patients receiving any of the following will be excluded: ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconazole, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. John's Wort.

Trial Contact Information

Trial Lead Organizations/Sponsors

Yale Cancer Center

PhytoCeutica, Incorporated

Wasif Saif, MDPrincipal Investigator

Lois Ravage-Mass, RNPh: 203-785-4991

Trial Sites

  New Haven
 Yale Cancer Center
 Lois Ravage-Mass, RN Ph: 203-785-4991
 Lynne Lamb, R.N. Ph: 203-737-2562
 Wasif Saif, MDPrincipal Investigator

Link to the current record.
NLM Identifer NCT00730158 processed this data on October 17, 2013

Note: Information about this trial is from the database. The versions designated for health professionals and patients contain the same text. Minor changes may be made to the record to standardize the names of study sponsors, sites, and contacts. only lists sites that are recruiting patients for active trials, whereas lists all sites for all trials. Questions and comments regarding the presented information should be directed to

Back to TopBack to Top